Analyst Price Targets — ARDT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 8:08 pm | Ben Hendrix | RBC Capital | $13.00 | $9.17 | StreetInsider | Ardent Health Partners Inc (ARDT) PT Lowered to $13 at RBC Capital |
| December 18, 2025 1:13 pm | — | UBS | $14.00 | $8.94 | TheFly | Ardent Health price target lowered to $14 from $14.50 at UBS |
| December 18, 2025 12:06 pm | Ann Hynes | Mizuho Securities | $12.00 | $8.94 | TheFly | Ardent Health price target lowered to $12 from $20 at Mizuho |
| November 18, 2025 11:51 am | — | Mizuho Securities | $13.00 | $8.70 | TheFly | Ardent Health price target lowered to $13 from $20 at Mizuho |
| November 14, 2025 8:59 pm | Whit Mayo | Leerink Partners | $16.00 | $9.01 | TheFly | Ardent Health price target lowered to $16 from $23 at Leerink |
| November 14, 2025 1:30 pm | — | Truist Financial | $13.00 | $8.92 | TheFly | Ardent Health price target lowered to $13 from $21 at Truist |
| November 14, 2025 1:27 pm | Ben Hendrix | RBC Capital | $16.00 | $8.97 | StreetInsider | Ardent Health Partners Inc (ARDT) PT Lowered at RBC Capital Amid Near-Term Headwind |
| November 14, 2025 10:11 am | — | Morgan Stanley | $12.00 | $9.30 | TheFly | Ardent Health downgraded to Equal Weight from Overweight at Morgan Stanley |
| October 14, 2025 9:02 am | — | Goldman Sachs | $19.00 | $14.13 | TheFly | Ardent Health initiated with a Neutral at Goldman Sachs |
| September 10, 2025 9:02 am | — | UBS | $17.00 | $13.03 | TheFly | Ardent Health initiated with a Buy at UBS |
Latest News for ARDT
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its first quarter 2026 results after the market closes on Tuesday, May 5, 2026. A conference call will be held the following day, Wednesday, May 6, 2026, at 10 a.m. ET to review the Company's financial results and conduct a…
JPMorgan Chase and Co. lowered its position in shares of Ardent Health, Inc. (NYSE: ARDT) by 17.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 283,061 shares of the company's stock after selling 59,738 shares during the quarter. JPMorgan Chase and Co.
Ardent Health, Inc. (NYSE: ARDT - Get Free Report) has been assigned an average recommendation of "Hold" from the fourteen research firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company.
NEW YORK, March 18, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ardent Health, Inc. (NYSE: ARDT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Ardent Health caused the company to misrepresent or fail to disclose that: (1) Ardent Health did not primarily rely on "detailed…
Shares of Ardent Health, Inc. (NYSE: ARDT - Get Free Report) have received an average rating of "Hold" from the thirteen research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and seven have issued a buy recommendation on
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARDT.
U.S. House Trading
No House trades found for ARDT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.